Prognostic impact of bleomycin-induced pneumonitis on the outcome of Hodgkin's lymphoma

Annals of Hematology

Volumn 90, Issue 1, 2011, Pages 67-72

  Ngeow, Joanne ^a   Tan, Iain B ^a   Kanesvaran, Ravindran ^a   Tan, Huey Ching ^a   Tao, Miriam ^a   Quek, Richard ^a   Lim, Soon Thye ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Bleomycin; Hodgkin disease; Toxicity

Indexed keywords

ALBUMIN; BLEOMYCIN; CORTICOSTEROID; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISOLONE; VINBLASTINE;

ADOLESCENT; ADULT; AGE; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; ASIAN; BLEOMYCIN INDUCED PNEUMONITIS; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CHILD; CLASSICAL HODGKIN LYMPHOMA; CLASSICAL LYMPHOCYTE HODGKIN LYMPHOMA; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FEMALE; FREEDOM FROM TREATMENT FAILURE; HODGKIN DISEASE; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LUNG FIBROSIS; LUNG FUNCTION; LUNG INFILTRATE; LUNG INTERSTITIUM; LYMPHOCYTE-RICH CLASSICAL HODGKIN LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MIXED CELLULARITY HODGKIN LYMPHOMA; MULTIPLE CYCLE TREATMENT; NODULAR SCLEROSIS HODGKIN LYMPHOMA; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIATION EXPOSURE; RETROSPECTIVE STUDY; RISK FACTOR; SCHOOL CHILD; SMOKING; SURVIVAL RATE; SYMPTOM; THORAX RADIOGRAPHY; TRANSBRONCHIAL BIOPSY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; BLEOMYCIN; CHILD; DATABASES, FACTUAL; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; PNEUMONIA; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78651292211     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-010-1032-z     Document Type: Article

References (13)

1. A Engert, et al. 2007 Two cycles of doxorubicin, bleomycin, vinblastine and dacarbazine plus extended field radiotherapy is superior to radiotherapy alone in early favourable Hodgkin's lymphoma: final results of the GHSG HD7 trial J Clin Oncol 25 3495 3502 1:CAS:528:DC%2BD2sXhtVajsbzL 10.1200/JCO.2006.07.0482 17606976 (Pubitemid 47310889)
2. Engert, et al. 2003 Involved field radiotherapy is equally effective and less toxic compared with extended field radiotherapy after four cycles of chemotherapy in patients with early stage unfavourable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group J Clin Oncol 21 3601 3608 10.1200/JCO.2003.03.023 12913100 (Pubitemid 46594052)
3. V Diehl, et al. 2003 Standard and increased dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's Disease N Engl J Med 348 2386 2395 1:CAS:528:DC%2BD3sXksFKgtb8%3D 10.1056/NEJMoa022473 12802024 (Pubitemid 36682817)
4. GP Canellos JR Anderson KJ Propert, et al. 1992 Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD or MOPP alternating with ABVD N Engl J Med 327 1478 1484 1:STN:280:DyaK3s%2FisVyisQ%3D%3D 10.1056/NEJM199211193272102 1383821
5. DB Duggan GR Petroni JL Johnson, et al. 2003 Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial J Clin Oncol 21 607 614 1:CAS:528:DC%2BD2cXpsVGrtbg%3D 10.1200/JCO.2003.12.086 12586796 (Pubitemid 46621893)
6. JM Connors P Klimo G Adams, et al. 1997 Treatment of advanced Hodgkin's disease with chemotherapy: comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from National Cancer Institute of Canada clinical trials group J Clin Oncol 15 1638 1645 1:CAS:528: DyaK2sXivVehsLs%3D 9193364
7. S Sleijfer 2001 Bleomycin induced pneumonitis Chest 120 617 624 1:CAS:528:DC%2BD3MXmsF2rtbk%3D 10.1378/chest.120.2.617 11502668 (Pubitemid 32881285)
8. BM Lewis R Izbicki 1980 Routine pulmonary function tests during bleomycin therapy: tests may be ineffective and potentially misleading JAMA 243 347 351 1:STN:280:DyaL3c%2FpslektQ%3D%3D 10.1001/jama.243.4.347 6153225 (Pubitemid 10212817)
9. D Hasenclever V Diehl, et al. 1998 A prognostic score for advanced Hodgkin's disease: International Prognostic Factors Project on Advanced Hodgkin's Disease N Engl J Med 339 1506 1514 1:STN:280:DyaK1M%2FisFenuw%3D%3D 10.1056/NEJM199811193392104 9819449 (Pubitemid 28543499)
10. W Martin K Ristow T Habermann J Colgan T Witzig S Ansell 2005 Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma J Clin Oncol 23 7614 7620 1:CAS:528:DC%2BD2MXht1Wrsr3P 10.1200/JCO.2005.02.7243 16186594 (Pubitemid 46291825)
11. E deHaas N Zwart C Meijer, et al. 2008 Variation in bleomycin hydrolase gene is associated with reduced survival after chemotherapy for testicular germ cell tumor J Clin Oncol 26 1817 1823 10.1200/JCO.2007.14.1606
12. AB Simpson J Paul J Graham, et al. 1998 Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-1995: a review of patients with germ cell tumors Br J Cancer 78 1061 1:STN:280:DyaK1M%2Fgs1KgtQ%3D%3D 9792151
13. J Matthews 1993 Pulmonary toxicity of ABVD chemotherapy and G-CSF in Hodgkin's disease: possible synergy Lancet 342 988 1:STN:280: DyaK2c%2FhvVWksQ%3D%3D 10.1016/0140-6736(93)92033-P 7692199